出典: meddic


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2013/09/09 14:03:26」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • Reversible Hypotony and Choroidal Effusion Following the Use of Pergolide for Parkinson's Disease.
  • Andreatta W1, Shah P.
  • Seminars in ophthalmology.Semin Ophthalmol.2015 Aug 21:1-3. [Epub ahead of print]
  • PURPOSE: To alert clinicians of the possibility of reversible drug-induced occult hypotony and choroidal effusion following the long-term use of pergolide.METHODS: Annotations were made while the case was observed. The clinical records of the patient were reviewed retrospectively.RESULTS: A 74-year-
  • PMID 24251433
  • Trends in inpatient antiparkinson drug use in the USA, 2001-2012.
  • Crispo JA1, Fortin Y, Thibault DP, Emons M, Bjerre LM, Kohen DE, Perez-Lloret S, Mattison D, Willis AW, Krewski D.
  • European journal of clinical pharmacology.Eur J Clin Pharmacol.2015 Aug;71(8):1011-9. doi: 10.1007/s00228-015-1881-4. Epub 2015 Jun 18.
  • PURPOSE: Although therapeutic options and clinical guidelines for Parkinson's disease (PD) have changed significantly in the past 15 years, prescribing trends in the USA remain unknown. The purpose of this population-based cohort study was to examine patterns of inpatient antiparkinson drug use bet
  • PMID 26081062
  • Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy.
  • Italiano D1, Bianchini E, Ilardi M, Cilia R, Pezzoli G, Zanettini R, Vacca L, Stocchi F, Bramanti P, Ciurleo R, Di Lorenzo G, Polimeni G, de Luise C, Ross D, Rijnbeek P, Sturkenboom M, Trifirò G.
  • Journal of neural transmission (Vienna, Austria : 1996).J Neural Transm.2015 Jun;122(6):799-808. doi: 10.1007/s00702-014-1314-z. Epub 2014 Sep 18.
  • On June 2008, the European Medicines Agency (EMA) introduced changes to the Summary of Product Characteristics (SPC) for cabergoline and pergolide, to reduce the risk of cardiac valvulopathy in users of these drugs. To assess the effectiveness of EMA recommendations in Italian clinical practice, we
  • PMID 25230720


  • 医薬品のリスク・マネジメントにおけるエビデンス診療ギャップ:レセプト分析からの視点
  • 中山 健夫
  • 薬学雑誌. 乙号 132(5), 549-554, 2012
  • … The receipt analysis showed that more than 70% of Parkinson's disease patients prescribed with cabergoline or pergolide did not undergo echocardiography despite the revision of the product label recommendation. …
  • NAID 130001888669
  • Echocardiography for the Detection of Valvulopathy Associated with the Use of Ergot-Derived Dopamine Agonists in Patients with Parkinson's Disease
  • Nakaoka Sachiko,Ishizaki Tatsuro,Urushihara Hisashi,Satoh Toshihiko,Ikeda Shunya,Morikawa Kaoru,Nakayama Takeo
  • Internal Medicine 50(7), 687-694, 2011
  • … Objective The ergot-derived dopamine agonists, cabergoline and pergolide, are associated with valvulopathy risk. … This study assessed changes in echocardiography evaluation of patients with Parkinson's disease (PD) taking cabergoline or pergolide before and after the label revision and examined the factors related with echocardiography performance. …
  • NAID 130000650040
  • Retroperitoneal Fibrosis Secondary to Pergolide Therapy
  • Fukae Jiro,Tanaka Shigeki,Hattori Nobutaka
  • Internal Medicine 49(15), 1687-1687, 2010
  • NAID 130000299610


Pergolide official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more. ... Events Observed During the Premarketing Evaluation of Pergolide Mesylate This ...
Pergolide (trade names Permax, Prascend) is an ergoline-based dopamine receptor agonist used in some countries for the treatment of Parkinson's disease. Parkinson's disease is associated with low levels of the neurotransmitter dopamine ...



拡張検索pergolide mesilate



メシル酸ペルゴリド pergolide mesilate
ペルマックス Permaxベセラールペルゴリン





pergolide mesilate」